Mumbai-based Glenmark has introduced a cut-price version of Merck's diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), on the Indian market ahead of the expected 2017 patent expiry date for the compounds. With Glenmark maintaining that its products are ‘non-infringing’, Merck – which has already made at least two separate attempts to adapt its commercial strategy to Indian conditions - will have to decide whether it wants to get involved in a David-versus-Goliath intellectual property rights battle.
Pre-expiry Januvia generics may test Merck’s resolve in India
Mumbai-based Glenmark has introduced a cut-price version of Merck's diabetes therapies, Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), on the Indian market ahead of the expected 2017 patent expiry date for the compounds. With Glenmark maintaining that its products are ‘non-infringing’, Merck – which has already made at least two separate attempts to adapt its commercial strategy to Indian conditions - will have to decide whether it wants to get involved in a David-versus-Goliath intellectual property rights battle.
More from Alimentary/Metabolic
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
More from Therapeutic Category
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.